Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Events:

Patient Centricity and Engagement Conference 2021

Webcast:

UX beyond the website: Insights for the age of omnichannel

News:

MedTech Qualitative Specialist joins Research Partnership

Guide

How to embrace behavioural science principles in healthcare MR

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

‘Smear Word’ campaign for Roche aims to break taboos and save lives

An all-female team at Mind+Matter has created a campaign for Roche that takes a tongue-in-cheek approach to tackle taboos about going for a smear test.

Video

Virtual Conference Live

Report

Digital Health Tools - Physician Trends

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan